Locoregional therapy in hepatocellular carcinoma: when to start and when to stop and when to revisit

With increasing therapeutic options available for advanced hepatocellular carcinoma (HCC), the timing and sequencing of locoregional and systemic therapy need to be re-examined. This is especially so for patients with intermediate HCC, so as to optimize responses while preserving liver reserves, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, J.J.X., Tai, D.W.-M., Choo, S.P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8086015/
https://www.ncbi.nlm.nih.gov/pubmed/33887687
http://dx.doi.org/10.1016/j.esmoop.2021.100129

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8086015/
https://www.ncbi.nlm.nih.gov/pubmed/33887687
http://dx.doi.org/10.1016/j.esmoop.2021.100129

Ejemplares similares